SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at AACR
DUBLIN, Calif., April 04, 2007 /PRNewswire-FirstCall/ -- SuperGen Inc. announced today that it will have multiple presentations at the American Association for Cancer Research Annual Meeting on April 14-18 in Los Angeles. These presentations will focus on data concerning many of SuperGen's current oncology programs including its lead tyrosine kinase inhibitor compound, MP470 and its ability to block Rad51, a key protein target involved in cancer cell drug resistance. Presentations will take place in the exhibit hall of the Los Angeles Convention Center.
The schedule of SuperGen's presentations is:
Poster
Date Time (PDT) Title Number/Section
Sunday, 1 p.m. - 5 p.m. Hydrochloride salt of #1540
April MP470, a potent
15 suppressor of Rad51, Poster
improves Section 31
bioavailability and
tolerability
Monday, 8 a.m. - 12 p.m. Discovery and #2380
April characterization of a
16 series of Axl kinase Poster
inhibitors using the Section 30
CLIMB(TM) process
Monday, 8 a.m. - 12 p.m. Discovery and #2387
April characterization of
16 small molecule Poster
inhibitors for Jak2 Section 30
Monday, 8 a.m. - 12 p.m. Zebrafish as a model #2229
April mechanistic screen
16 for small molecule Poster
inhibitors of DNMT1 Section 23
Monday, 1 p.m. - 5 p.m. Discovery and #3261
April development of MP529,
16 a new effective and Poster
selective inhibitor Section 29
of Aurora A kinase
Tuesday, 8 a.m. - 12 p.m. MP470, a potent #4028
April suppressor of Rad51,
17 improves response to Poster
platinum-based Section 29
anticancer agents
Tuesday, 10:40 a.m. - Novel DNA #4142
April 10:55 a.m. hypomethylating
17 agents: non- Minisymposium
nucleoside compounds Cancer
that do not Epigenetics
incorporate into DNA
selectively induce Room 304 A-C
degradation of DNA
methyltransferase I
(DNMT1) in human
cancer cells by the
proteasomal pathway
and re-express
silenced tumor
suppressor genes
Wed., 8 a.m. - 12 p.m. Dual inhibition of #5421
April receptor tyrosine
18 kinases of PDGFR and Poster
EGFR abolishes Section 20
prostate cancer cell
growth in culture and
in a mouse xenograft
model by complete
dephosphorylation of
PKB/Akt
About SuperGen
Based in Dublin, Calif., SuperGen is a pharmaceutical company dedicated to the discovery, acquisition, rapid development and commercialization of therapies for solid tumors and hematological malignancies. SuperGen is developing a number of therapeutic anticancer products focused on inhibitors of aurora-A, tyrosine kinase and DNA methyltransferase. For more information about SuperGen, please visit http://www.supergen.com.
This news release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as "believes," "expects," "anticipates," "intends," "will," "may," "should," or similar expressions. These forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that may cause actual results to differ materially from the results discussed in these statements. Factors that might cause the company's results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, the ability to discover, develop and move target compounds into clinical development and other risks and uncertainties detailed from time to time in the company's filings with the Securities and Exchange Commission including its most recently filed Form 10-Q and 10-K. SuperGen, Inc. undertakes no duty to update any of these forward-looking statements to conform them to actual results.
Contacts:
SuperGen Noonan Russo
Timothy L. Enns Greg Geissman
S.V.P., Corporate Communications Director of Media Relations
& Business Development
(925) 560-0100 x111 (619) 814-3510
tenns@supergen.com greg.geissman@eurorscg.com
CONTACT: Timothy L. Enns, S.V.P., Corporate Communications & BusinessDevelopment, of SuperGen, +1-925-560-0100 x111, ; or GregGeissman, Director of Media Relations, of Noonan Russo, +1-619-814-3510, tenns@supergen.com greg.geissman@eurorscg.com
Web site: http://www.supergen.com/
Ticker Symbol: (NASDAQ-NMS:SUPG)
Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights
reserved.
A United Business Media Company
Posted: April 2007
